US FDA approved Lynparza for pancreatic cancer
30 December 2019 07:00 GMT Lynparza approved in the US as a 1st-line maintenance treatmentof germline BRCA-mutated metastatic pancreatic cancer Lynparza reduced the risk of disease progression or death by 47% in patientswhose disease had not progressed on at least 16 weeks of a 1st-line platinum-based chemotherapy regimen Only PARP inhibitor approved in germline BRCA-mutatedmetastatic pancreatic cancer AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been